Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $5.77.
A number of brokerages have recently issued reports on CTMX. Wedbush raised shares of CytomX Therapeutics from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $3.00 to $8.00 in a research note on Thursday, May 9th. JPMorgan Chase & Co. raised CytomX Therapeutics from an “underweight” rating to a “neutral” rating in a report on Monday, April 22nd. Jefferies Financial Group raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and raised their target price for the company from $2.50 to $8.00 in a research note on Monday, May 6th. BMO Capital Markets boosted their target price on CytomX Therapeutics from $3.25 to $3.59 and gave the stock a “market perform” rating in a research report on Thursday, May 9th. Finally, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a report on Thursday.
View Our Latest Stock Report on CTMX
Hedge Funds Weigh In On CytomX Therapeutics
CytomX Therapeutics Price Performance
NASDAQ:CTMX opened at $1.22 on Friday. The firm has a market capitalization of $95.06 million, a price-to-earnings ratio of 6.10 and a beta of 1.14. The business has a fifty day moving average price of $1.97 and a 200-day moving average price of $1.87. CytomX Therapeutics has a one year low of $1.04 and a one year high of $5.85.
CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.23. The company had revenue of $41.46 million during the quarter, compared to the consensus estimate of $23.40 million. CytomX Therapeutics had a negative return on equity of 30.70% and a net margin of 13.87%. On average, equities research analysts expect that CytomX Therapeutics will post -0.14 earnings per share for the current fiscal year.
About CytomX Therapeutics
CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
Featured Articles
- Five stocks we like better than CytomX Therapeutics
- Stock Splits, Do They Really Impact Investors?
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- What Are Dividend Challengers?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.